• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alumis Inc. - Common Stock (NQ:ALMS)

    3.990 -0.150 (-3.62%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Alumis Inc. - Common Stock

    ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
    From ACELYRIN, INC.
    Via GlobeNewswire
    Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
    ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today 
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
    From ACELYRIN, INC.
    Via GlobeNewswire
    Alumis and ACELYRIN Announce Amended Merger Agreement
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
    From ACELYRIN, INC.
    Via GlobeNewswire
    ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
    From ACELYRIN, INC.
    Via GlobeNewswire
    Alumis to Participate in Upcoming September Investor Conferences
    From Alumis Inc.
    Via GlobeNewswire
    Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
    From Alumis Inc.
    Via GlobeNewswire
    Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
    From Alumis Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.